ArticleEClinicalMedicine2024

Sustained improvements in patient-reported outcomes after long-term sutimlimab in patients with cold agglutinin disease: results from the CADENZA study open-label extension.

Alexander Röth et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.